Recent corporate updates from NervGen Pharma highlight substantial clinical progress regarding preparations for its Phase 3 RESTORE registrational study for chronic spinal cord injury. Additional press releases detail robust cash runway metrics following financing rounds, ongoing clinical trial site activations, and management's active engagement with patient advocacy and medical communities.